[免疫检查点通过代谢途径调节瘤的免疫调节]
Weiguang Du1, Xiyang Tang2, Yulong Zhou2
1Graduate School of Xi'an Medical University, Xi'an 710021, China.
Zhongguo fei ai za zhi = Chinese journal of lung cancer
|April 10, 2025
概括
免疫检查点调节细胞代谢,影响癌症治疗的有效性. 针对检查点和代谢途径,可以克服瘤免疫抵抗力.
科学领域:
- 免疫学 免疫学 免疫学
- 代谢调节 代谢调节 代谢调节
- 癌症治疗 癌症治疗
背景情况:
- 免疫检查点 (例如PD-1,CTLA-4) 对于免疫细胞功能至关重要.
- 免疫检查点抑制剂 (ICI) 显示出治疗前景,但面临治疗无效和免疫抵抗等挑战.
- 新出现的证据将免疫检查点与细胞代谢联系起来,影响免疫反应和瘤进展.
研究的目的:
- 审查免疫检查点蛋白 (PD-1,CTLA-4,TIGIT,TIM-3,CD47,IDO1) 在调节代谢重编程中的机制.
- 探索针对免疫检查点和代谢途径的"双重调节"策略的潜力,以克服瘤免疫抵抗.
主要方法:
- 关于免疫检查点,细胞代谢和癌症免疫学的科学文章的文献综述.
- 分析特定免疫检查点影响瘤和免疫细胞代谢的机制.
- 综合发现,以评估治疗策略.
主要成果:
- 免疫检查点调节瘤细胞的代谢重编程,影响免疫细胞的营养可用性.
- 免疫检查点调节免疫细胞的代谢途径 (例如PI3K/AKT/mTOR),影响免疫细胞的激活.
- 特定的检查点如PD-1,CTLA-4,TIGIT,TIM-3,CD47和IDO1都与代谢调节有关.
结论:
- 免疫检查点蛋白与细胞代谢有显著的相互作用.
- 针对免疫检查点和代谢途径同时提供了一种有希望的方法来提高癌症免疫疗法的疗效和克服耐药性.
更多相关视频
相关概念视频
Tumor Immunotherapy
411
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
411
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Adaptive Mechanisms in Cancer Cells
5.6K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.6K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


